Nuclear maspin expression correlates with the CpG island methylator phenotype and tumor aggressiveness in colorectal cancer

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 2, 2015, Pages 1920-1928

  Kim, Jung Ho ^a   Cho, Nam Yun ^b   Bae, Jeong Mo ^b   Kim, Kyung Ju ^b   Rhee, Ye Young ^b   Lee, Hye Seung ^c   Kang, Gyeong Hoon ^b  

^a Seoul National University Boramae Hospital   (South Korea)

^b Seoul National University   (South Korea)

^c Seoul National University Bundang Hospital   (South Korea)

Author keywords

Colorectal cancer; CpG island methylator phenotype; Maspin; Microsatellite instability; Prognosis; SERPINB5

Indexed keywords

SERINE PROTEINASE INHIBITOR; SERPIN-B5; TUMOR MARKER;

CANCER STAGING; CELL NUCLEUS; CHEMISTRY; CLINICAL TRIAL; COLORECTAL TUMOR; CPG ISLAND; DISEASE FREE SURVIVAL; DNA METHYLATION; FEMALE; GENETIC PREDISPOSITION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PHENOTYPE; POLYMERASE CHAIN REACTION; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SOUTH KOREA; TUMOR INVASION;

BIOMARKERS, TUMOR; CELL NUCLEUS; COLORECTAL NEOPLASMS; CPG ISLANDS; DISEASE-FREE SURVIVAL; DNA METHYLATION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PHENOTYPE; POLYMERASE CHAIN REACTION; PROPORTIONAL HAZARDS MODELS; REPUBLIC OF KOREA; RISK FACTORS; SERPINS;

EID: 84928128192     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Bodenstine TM, Seftor RE, Khalkhali-Ellis Z, Seftor EA, Pemberton PA and Hendrix MJ. Maspin: molecular mechanisms and therapeutic implications. Cancer Metastasis Rev 2012; 31: 529-551.
2. Berardi R, Morgese F, Onofri A, Mazzanti P, Pistelli M, Ballatore Z, Savini A, De Lisa M, Caramanti M, Rinaldi S, Pagliaretta S, Santoni M, Pierantoni C and Cascinu S. Role of maspin in cancer. Clin Transl Med 2013; 2: 8.
3. Machowska M, Wachowicz K, Sopel M and Rzepecki R. Nuclear location of tumor suppressor protein maspin inhibits proliferation of breast cancer cells without affecting proliferation of normal epithelial cells. BMC Cancer 2014; 14: 142.
4. Berardi R, Santinelli A, Onofri A, Brunelli A, Pierantoni C, Pisa E, Pagliacci A, Stramazzotti D, Zuccatosta L, Mazzanti P, Sabbatini A, Gasparini S, Bearzi I and Cascinu S. Maspin expression is a favorable prognostic factor in non-small cell lung cancer. Anal Quant Cytol Histol 2012; 34: 72-78.
5. Marioni G, Blandamura S, Giacomelli L, Calgaro N, Segato P, Leo G, Fischetto D, Staffieri A and de Filippis C. Nuclear expression of maspin is associated with a lower recurrence rate and a longer disease-free interval after surgery for squamous cell carcinoma of the larynx. Histopathology 2005; 46: 576-582.
6. Dietmaier W, Bettstetter M, Wild PJ, Woenckhaus M, Rummele P, Hartmann A, Dechant S, Blaszyk H, Pauer A, Klinkhammer-Schalke M and Hofstadter F. Nuclear Maspin expression is associated with response to adjuvant 5-fluorouracil based chemotherapy in patients with stage III colon cancer. Int J Cancer 2006; 118: 2247-2254.
7. Markl B, Arnholdt HM, Jahnig H, Schenkirsch G, Herrmann RA, Haude K, Spatz H, Anthuber M, Schlimok G and Oruzio D. Shift from cytoplasmic to nuclear maspin expression correlates with shorter overall survival in node-negative colorectal cancer. Hum Pathol 2010; 41: 1024-1033.
8. Martinoli C, Gandini S, Luise C, Mazzarol G, Confalonieri S, Giuseppe Pelicci P, Testori A and Ferrucci PF. Maspin expression and melanoma progression: a matter of sub-cellular localization. Mod Pathol 2014; 27: 412-419.
9. Gurzu S, Szentirmay Z, Popa D and Jung I. Practical value of the new system for Maspin assessment, in colorectal cancer. Neoplasma 2013; 60: 373-383.
10. Bettstetter M, Woenckhaus M, Wild PJ, Rummele P, Blaszyk H, Hartmann A, Hofstadter F and Dietmaier W. Elevated nuclear maspin expression is associated with microsatellite instability and high tumour grade in colorectal cancer. J Pathol 2005; 205: 606-614.
11. Fung CL, Chan C, Jankova L, Dent OF, Robertson G, Molloy M, Bokey L, Chapuis PH, Lin BP and Clarke SJ. Clinicopathological correlates and prognostic significance of maspin expression in 450 patients after potentially curative resection of node-positive colonic cancer. Histopathology 2010; 56: 319-330.
12. Snoeren N, Emmink BL, Koerkamp MJ, van Hooff SR, Goos JA, van Houdt WJ, de Wit M, Prins AM, Piersma SR, Pham TV, Belt EJ, Bril H, Stockmann HB, Meijer GA, van Hillegersberg R, Holstege FC, Jimenez CR, Fijneman RJ, Kranenburg OW and Rinkes IH. Maspin is a marker for early recurrence in primary stage III and IV colorectal cancer. Br J Cancer 2013; 109: 1636-1647.
13. Bae JM, Kim JH and Kang GH. Epigenetic alterations in colorectal cancer: the CpG island methylator phenotype. Histol Histopathol 2013; 28: 585-595.
14. Kim JH, Shin SH, Kwon HJ, Cho NY and Kang GH. Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers. Virchows Arch 2009; 455: 485-494.
15. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN and Srivastava S. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998; 58: 5248-5257.
16. Lee DW, Kim KJ, Han SW, Lee HJ, Rhee YY, Bae JM, Cho NY, Lee KH, Kim TY, Oh DY, Im SA, Bang YJ, Jeong SY, Park KJ, Park JG, Kang GH and Kim TY. KRAS Mutation is Associated with Worse Prognosis in Stage III or High-risk Stage II Colon Cancer Patients Treated with Adjuvant FOLFOX. Ann Surg Oncol 2015; 22: 187-94.
17. Kim JH, Kim KJ, Rhee YY, Oh S, Cho NY, Lee HS and Kang GH. Expression status of wild-type HSP110 correlates with HSP110 T17 deletion size and patient prognosis in microsatellite-unstable colorectal cancer. Mod Pathol 2014; 27: 443-453.
18. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, Kang GH, Widschwendter M, Weener D, Buchanan D, Koh H, Simms L, Barker M, Leggett B, Levine J, Kim M, French AJ, Thibodeau SN, Jass J, Haile R and Laird PW. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 2006; 38: 787-793.
19. Gurzu S, Szentirmay Z, Toth E and Jung I. Possible predictive value of maspin expression in colorectal cancer. Recent Pat Anticancer Drug Discov 2013; 8: 183-190.
20. De Sousa EMF, Wang X, Jansen M, Fessler E, Trinh A, de Rooij LP, de Jong JH, de Boer OJ, van Leersum R, Bijlsma MF, Rodermond H, van der Heijden M, van Noesel CJ, Tuynman JB, Dekker E, Markowetz F, Medema JP and Vermeulen L. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat Med 2013; 19: 614-618.
21. Bae JM, Kim MJ, Kim JH, Koh JM, Cho NY, Kim TY and Kang GH. Differential clinicopathological features in microsatellite instability-positive colorectal cancers depending on CIMP status. Virchows Arch 2011; 459: 55-63.